Fig. 5: Collagen-degrading capacity of Man-MPs.

a Relative collagen content after soluble collagen I was incubated with MPs or Man-MPs at the concentration of 75 µg protein mL⁻¹ pretreated with or without 0.6 mg mL⁻¹ Bati or 100 μg mL⁻¹ AEBSF for 72 h measured by Sirius red total collagen detection kit. Data are presented as mean ± s.d. (n = 3 biologically independent samples; one-way ANOVA followed by Tukey’s HSD post-hoc test). b SHG imaging of tumor tissues of H22 tumor-bearing mice after intravenous injection of PBS, MPs, Man-MPs, free Met, Met@MPs or Met@Man-MPs at the Met dosage of 10 mg kg⁻¹, or high dosage of Met at 100 mg kg⁻¹ every two days for different times. Images are representative of three biologically independent mice. Scale bars: 50 μm. c Relative SHG signal intensity in tumor tissues of H22 tumor-bearing mice after treatment indicated in (b). Data are presented as mean ± s.d. (n = 10 fields for 3 mice; two-way ANOVA followed by Bonferroni’s multiple comparisons post-test). d Immunofluorescence analysis of collagen I (labeled with Cy3-conjugated collage I antibody, red) in tumor tissues of H22 tumor-bearing mice after intravenous injection of PBS, MPs, Man-MPs, free Met, Met@MPs or Met@Man-MPs at the Met dosage of 10 mg kg⁻¹, or high dosage of Met at 100 mg kg⁻¹ every two days for six times. The nuclei were stained by DAPI (blue). Images are representative of three biologically independent mice. Scale bars: 200 μm. e Relative collagen I-positive area in tumor tissues of H22 tumor-bearing mice after treatment indicated in (d). Data are presented as mean ± s.d. (n = 5 fields for 3 mice; one-way ANOVA followed by Tukey’s HSD post-hoc test). Source data are provided as a Source Data file.